Cost,ORGANIZATION
Benefit,ORGANIZATION
Analysis,ORGANIZATION
of,ORGANIZATION
Limited,ORGANIZATION
Reopening,ORGANIZATION
Relative,ORGANIZATION
to,O
a,O
Herd,O
Im,O
‐,O
munity,O
Strategy,O
or,O
Shelter,O
in,O
Place,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
the,O
United,ORGANIZATION
States,O
Robert,PERSON
B.,PERSON
Schonberger,PERSON
MD,STATE_OR_PROVINCE
MHS,O
.,O
a,O
Yair,PERSON
J.,PERSON
Listokin,PERSON
JD,O
PhD,O
.,O
b,O
Ian,PERSON
Ayres,PERSON
JD,O
PhD,O
.,O
c,O
Reza,PERSON
Yaesoubi,PERSON
PhD,O
.,O
d,O
Zachary,PERSON
R.,PERSON
Shelley,PERSON
BA,PERSON
.,O
e,O
Robert,PERSON
B.,PERSON
Schonberger,PERSON
Department,O
of,O
Anesthesiology,O
333,NUMBER
Cedar,O
Street,O
;,O
TMP,O
‐,O
3,NUMBER
New,O
Haven,O
.,O
CT,STATE_OR_PROVINCE
06520,NUMBER
Fierce,O
debate,O
about,O
the,O
health,O
and,O
financial,O
tradeoffs,O
presented,O
by,O
different,O
COVID,O
‐,O
19,NUMBER
pandemic,O
mitigation,O
strategies,O
highlights,O
the,O
need,O
for,O
rigorous,O
quantita,O
‐,O
tive,O
evaluation,O
of,O
policy,O
options,O
.,O
Objective,O
:,O
To,O
quantify,O
the,O
economic,O
value,O
of,O
the,O
costs,O
and,O
benefits,O
of,O
a,O
policy,O
of,O
continued,O
limited,O
reopening,O
with,O
social,O
distancing,O
relative,O
to,O
alternative,O
COVID,O
‐,O
19,NUMBER
response,O
strategies,O
in,O
the,O
United,COUNTRY
States,COUNTRY
.,O
Design,O
:,O
We,O
estimate,O
the,O
number,O
and,O
value,O
of,O
quality,O
‐,O
adjusted,O
life,O
‐,O
years,DURATION
(,O
QALY,O
),O
gained,O
from,O
mortality,O
averted,O
.,O
with,O
a,O
value,O
of,O
$,MONEY
125.000,MONEY
per,O
QALY,O
.,O
and,O
compare,O
these,O
benefits,O
to,O
the,O
associated,O
costs,O
in,O
terms,O
of,O
plausible,O
effects,O
on,O
US,COUNTRY
GDP,O
under,O
a,O
policy,O
of,O
continued,O
limited,O
reopening,O
with,O
social,O
distancing,O
relative,O
to,O
a,O
policy,O
of,O
full,O
reopening,O
toward,O
herd,O
immunity,O
.,O
Using,O
the,O
same,O
QALY,O
value,O
assumptions,O
.,O
we,O
further,O
evaluate,O
cost,O
‐,O
effectiveness,O
of,O
a,O
return,O
to,O
Shelter,O
‐,O
in,O
‐,O
Place,O
relative,O
to,O
a,O
policy,O
of,O
limited,O
reopening,O
.,O
Setting,O
:,O
United,COUNTRY
States,COUNTRY
Measurements,O
:,O
QALY,O
and,O
cost,O
as,O
percent,O
of,O
GDP,O
of,O
limited,O
reopening,O
with,O
continued,O
social,O
distancing,O
rela,O
‐,O
tive,O
to,O
a,O
strategy,O
of,O
full,O
reopening,O
aimed,O
at,O
achieving,O
herd,O
im,O
‐,O
munity,O
;,O
a,O
limited,O
reopening,O
budget,O
measured,O
in,O
the,O
number,O
of,O
months,DURATION
before,O
this,O
strategy,O
fails,O
to,O
demonstrate,O
cost,O
‐,O
effective,O
‐,O
ness,O
relative,O
to,O
a,O
full,O
reopening,O
;,O
a,O
shelter,O
‐,O
in,O
‐,O
place,O
threshold,O
measured,O
in,O
the,O
number,O
of,O
lives,O
saved,O
at,O
which,O
a,DURATION
month,DURATION
of,O
shel,O
‐,O
tering,O
in,O
place,O
demonstrates,O
cost,O
effectiveness,O
relative,O
to,O
the,O
limited,O
reopening,O
strategy,O
.,O
Results,O
:,O
QALY,O
benefits,O
from,O
mortali,O
‐,O
ty,O
averted,O
by,O
continued,O
social,O
distancing,O
and,O
limited,O
reopening,O
relative,O
to,O
a,O
policy,O
of,O
full,O
reopening,O
exceed,O
projected,O
GDP,O
costs,O
if,O
an,O
effective,O
vaccine,O
or,O
therapeutic,O
can,O
be,O
developed,O
within,O
11.1,DATE
months,DATE
from,DATE
late,DATE
May,DATE
2020,DATE
.,O
White,ORGANIZATION
House,ORGANIZATION
vaccine,O
projections,O
fall,DATE
within,O
this,O
date,O
.,O
supporting,O
a,O
partial,O
reopening,O
strategy,O
.,O
One,DURATION
month,DURATION
of,O
shelter,O
‐,O
in,O
‐,O
place,O
restrictions,O
provides,O
QALY,O
benefits,O
from,O
averted,O
mortality,O
that,O
exceed,O
the,O
associated,O
GDP,O
costs,O
rela,O
‐,O
tive,O
to,O
limited,O
reopening,O
if,O
the,O
restrictions,O
prevent,O
at,O
least,O
154.586,NUMBER
additional,O
COVID,O
‐,O
19,NUMBER
deaths,O
over,O
the,O
course,O
of,O
the,O
pandem,O
‐,O
ic,O
.,O
Current,DATE
models,O
of,O
disease,CAUSE_OF_DEATH
progression,O
suggest,O
that,O
limited,O
reopening,O
will,O
not,O
cause,O
this,O
many,O
additional,O
deaths,O
.,O
again,O
sup,O
‐,O
porting,O
a,O
limited,O
reopening,O
strategy,O
.,O
Limitation,O
:,O
Limited,O
hori,O
‐,O
zon,O
of,O
COVID,O
‐,O
19,NUMBER
mortality,O
projections,O
;,O
infection,CAUSE_OF_DEATH
fatality,O
ratio,O
mortality,O
and,O
the,O
deployment,O
of,O
partially,O
effective,O
therapeutics,O
to,O
decrease,O
mortality,O
;,O
effect,O
on,O
GDP,O
modeled,O
as,O
constant,O
within,O
a,O
given,O
phase,O
of,O
the,O
pandemic,O
;,O
accounts,O
for,O
age,O
and,O
sex,O
distribu,O
‐,O
tion,O
of,O
QALYs,O
.,O
but,O
not,O
effect,O
of,O
comorbidities,O
;,O
only,O
considers,O
impact,O
from,O
QALY,ORGANIZATION
lost,O
due,O
to,O
mortality,O
and,O
from,O
changes,O
in,O
GDP,O
.,O
excluding,O
numerous,O
other,O
considerations,O
.,O
such,O
as,O
non,O
‐,O
fatal,O
COVID,O
‐,O
19,NUMBER
morbidity,O
.,O
reduced,O
quality,O
of,O
life,O
caused,O
by,O
closures,O
and,O
restrictions,O
.,O
Conclusions,O
:,O
A,O
limited,O
reopening,O
to,O
achieve,O
partial,O
mitigation,O
of,O
COVID,O
‐,O
19,NUMBER
is,O
cost,O
effective,O
relative,O
to,O
a,O
full,O
reopening,O
if,O
an,O
effective,O
therapeutic,O
or,O
vaccine,O
can,O
be,O
de,O
‐,O
ployed,O
within,O
11.1,DATE
months,DATE
of,DATE
late,DATE
May,DATE
2020,DATE
.,O
One,NUMBER
additional,O
month,DURATION
of,O
shelter,O
‐,O
in,O
‐,O
place,O
restrictions,O
should,O
only,O
be,O
imposed,O
if,O
it,O
saves,O
at,O
least,O
154.586,NUMBER
lives,O
per,O
month,DURATION
before,O
the,O
development,O
of,O
an,O
effective,O
therapeutic,O
or,O
vaccine,O
relative,O
to,O
limited,O
reopen,O
‐,O
ing,O
.,O
Funding,O
:,O
This,O
work,O
was,O
supported,O
in,O
part,O
by,O
grant,O
K01AI119603,O
from,O
the,O
National,O
represent,O
the,O
opinions,O
of,O
the,O
NI,MISC
‐,O
AID,O
.,O
the,O
NIH,ORGANIZATION
.,O
or,O
the,O
United,COUNTRY
States,COUNTRY
Government,O
.,O
MANUSCRIPT,O
BODY,O
:,O
As,O
the,O
national,O
response,O
to,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
evolves,O
.,O
the,O
difficult,O
health,O
and,O
financial,O
tradeoffs,O
posed,O
by,O
prolonged,O
pub,O
‐,O
lic,O
health,O
restrictions,O
have,O
grown,O
increasingly,O
stark,O
.,O
In,O
this,O
context,O
.,O
we,O
quantify,O
the,O
value,O
of,O
Quality,O
Adjusted,O
Life,O
Years,DURATION
(,O
QALY,O
),O
saved,O
(,O
or,O
lost,O
),O
by,O
a,O
limited,O
reopening,O
with,O
continued,O
so,O
‐,O
cial,O
distancing,O
as,O
compared,O
to,O
both,O
a,O
pandemic,O
scenario,O
that,O
ends,O
with,O
herd,O
immunity,O
and,O
a,O
return,O
to,O
shelter,O
‐,O
in,O
‐,O
place,O
.,O
We,O
compare,O
these,O
benefits,O
to,O
the,O
associated,O
costs,O
in,O
terms,O
of,O
plausible,O
ef,O
‐,O
fects,O
on,O
US,COUNTRY
We,O
provide,O
estimates,O
of,O
the,O
number,O
of,O
months,DURATION
.,O
beyond,O
May,DATE
26,DATE
.,DATE
2020,DATE
.,O
that,O
the,O
strategy,O
of,O
limited,O
economic,O
and,O
social,O
reopening,O
present,DATE
on,O
that,O
date,O
demonstrates,O
cost,O
‐,O
effectiveness,O
relative,O
to,O
full,O
reopening,O
.,O
We,O
also,O
provide,O
a,O
threshold,O
number,O
of,O
lives,O
saved,O
at,O
which,O
one,DURATION
month,DURATION
of,O
shelter,O
‐,O
in,O
‐,O
place,O
limitations,O
would,O
demonstrate,O
costeffectiveness,O
relative,O
to,O
the,O
limited,O
re,O
‐,O
opening,O
strategy,O
.,O
Methods,O
and,O
Findings,O
:,O
We,O
use,O
cost,O
benefit,O
analysis,O
(,O
1,NUMBER
),O
to,O
compare,O
the,O
economic,O
cost,O
of,O
a,O
continuation,O
of,O
limited,O
reopening,O
with,O
social,O
distancing,O
at,O
levels,O
that,O
were,O
present,DATE
on,O
May,DATE
26,DATE
.,DATE
2020,DATE
.,O
with,O
the,O
economic,O
value,O
of,O
mortality,O
averted,O
by,O
this,O
policy,O
as,O
compared,O
to,O
a,O
pandemic,O
ending,O
in,O
late,O
January,DATE
2021,DATE
with,O
herd,O
immunity,O
.,O
We,O
also,O
provide,O
a,O
cost,O
benefit,O
analysis,O
of,O
shelter,O
‐,O
in,O
‐,O
place,O
restrictions,O
relative,O
to,O
a,O
limited,O
economic,O
and,O
social,O
reopening,O
.,O
Our,O
analysis,O
adheres,O
to,O
the,O
Con,O
‐,O
solidated,O
Health,O
Economic,O
Evaluation,O
Reporting,O
Standards,O
reopen,O
‐,O
ing,O
is,O
compared,O
reflect,O
both,O
a,O
more,O
and,O
a,O
less,O
restrictive,O
policy,O
alternative,O
to,O
the,O
level,O
of,O
limited,O
reopening,O
that,O
was,O
in,O
place,O
on,O
May,DATE
26,DATE
.,DATE
2020,DATE
.,O
We,O
estimate,O
that,O
the,O
mortality,O
benefits,O
of,O
lim,O
‐,O
ited,O
reopening,O
versus,O
a,O
full,O
reopening,O
exceed,O
their,O
costs,O
so,O
long,O
as,O
such,O
policies,O
are,O
not,O
in,O
place,O
for,O
more,DURATION
than,DURATION
11.1,DURATION
months,DURATION
(,O
slightly,O
less,DURATION
than,DURATION
1,DURATION
year,DURATION
),O
before,O
the,O
discovery,O
and,O
implementa,O
‐,O
tion,O
of,O
an,O
effective,O
vaccine,O
or,O
therapeutic,O
.,O
The,O
estimate,O
of,O
a,O
limited,O
reopening,O
budget,O
allows,O
for,O
consideration,O
of,O
policy,O
al,O
‐,O
ternatives,O
in,O
light,O
of,O
the,O
readers,O
own,O
estimates,O
regarding,O
the,O
timing,O
of,O
these,O
developments,O
.,O
By,O
contrast,O
.,O
existing,O
cost,O
effec,O
‐,O
tiveness,O
analyses,O
of,O
COVID,O
‐,O
19,NUMBER
interventions,O
use,O
fixed,O
end,O
dates,O
.,O
(,O
3,NUMBER
.,O
4,NUMBER
),O
Such,O
analyses,O
implicitly,O
assume,O
that,O
a,O
vaccine,O
will,O
be,O
available,O
by,O
the,O
given,O
end,O
date,O
.,O
If,O
a,O
vaccine,O
is,O
not,O
available,O
on,O
the,O
ad,O
hoc,O
end,O
date,O
.,O
however,O
.,O
then,O
the,O
public,O
health,O
restric,O
‐,O
tions,O
under,O
study,O
have,O
simply,O
delayed,O
COVID,O
‐,O
19,NUMBER
mortality,O
rather,O
than,O
prevented,O
it,O
.,O
radically,O
changing,O
the,O
costeffectiveness,O
eval,O
‐,O
uation,O
.,O
The,O
11.1,NUMBER
‐,O
month,DURATION
limited,O
reopening,O
budget,O
(,O
before,O
limited,O
reopening,O
fails,O
to,O
demonstrate,O
cost,O
‐,O
effectiveness,O
),O
depends,O
.,O
of,O
course,O
.,O
on,O
many,O
assumptions,O
.,O
which,O
we,O
plot,O
the,O
cost,O
‐,O
effectiveness,O
of,O
limited,O
reopening,O
versus,O
full,O
reopening,O
under,O
varying,O
the,O
lim,O
‐,O
ited,O
reopening,O
budget,O
.,O
enabling,O
the,O
user,O
to,O
conduct,O
their,O
own,O
sensitivity,O
analysis,O
.,O
We,O
provide,O
further,O
elaboration,O
of,O
the,O
lim,O
‐,O
ited,O
reopening,O
budget,O
concept,O
in,O
the,O
discussion,O
below,O
.,O
Using,O
the,O
same,O
assumptions,O
regarding,O
QALY,ORGANIZATION
value,O
.,O
we,O
find,O
that,O
shelter,O
‐,O
in,O
‐,O
place,O
restrictions,O
are,O
unlikely,O
to,O
demonstrate,O
cost,O
‐,O
effectiveness,O
relative,O
to,O
a,O
limited,O
reopening,O
strategy,O
.,O
The,O
economic,O
harms,O
as,O
‐,O
sociated,O
with,O
shelter,O
‐,O
in,O
‐,O
place,O
exceed,O
the,O
value,O
of,O
QALY,O
benefits,O
unless,O
one,NUMBER
additional,O
month,DURATION
of,O
shelter,O
‐,O
in,O
‐,O
place,O
restrictions,O
would,O
prevent,O
more,O
than,O
154.586,NUMBER
deaths,O
.,O
both,O
during,O
that,O
month,DURATION
and,O
in,O
subsequent,O
time,O
periods,O
before,O
an,O
effective,O
vaccine,O
or,O
therapeutic,O
is,O
deployed,O
.,O
Most,O
models,O
.,O
however,O
.,O
project,O
that,O
added,O
mortality,O
from,O
limited,O
opening,O
falls,O
well,O
below,O
this,O
shelter,O
‐,O
in,O
‐,O
place,O
threshold,O
.,O
Even,O
if,O
shelter,O
‐,O
in,O
‐,O
place,O
restrictions,O
prevent,O
more,O
than,O
154.586,NUMBER
deaths,O
in,O
a,O
particular,O
month,DURATION
.,O
if,O
the,O
restric,O
‐,O
tions,O
merely,O
delay,O
the,O
deaths,O
rather,O
than,O
completely,O
preventing,O
them,O
through,O
the,O
time,O
that,O
a,O
vaccine,O
is,O
deployed,O
.,O
then,O
the,O
addi,O
‐,O
tional,O
restrictions,O
fail,O
cost,O
‐,O
benefit,O
analysis,O
.,O
We,O
assume,O
that,O
recovery,O
from,O
COVID,O
‐,O
19,NUMBER
confers,O
total,O
or,O
partial,O
immunity,O
for,O
a,O
long,O
‐,O
enough,O
period,O
to,O
develop,O
an,O
effective,O
vaccine,O
or,O
therapeutic,O
before,O
the,O
disease,CAUSE_OF_DEATH
spreads,O
again,O
.,O
We,O
further,O
assume,O
that,O
in,O
a,O
herd,O
immunity,O
strategy,O
.,O
pandemic,O
COVID19,O
mortality,O
would,O
be,O
1.762.788,NUMBER
.,O
This,O
number,O
is,O
derived,O
by,O
extending,O
the,O
Penn,LOCATION
Wharton,CITY
epidemiological,O
model,TITLE
(,O
5,NUMBER
),O
Full,O
Reopening,O
policy,O
scenario,O
and,O
Re,O
‐,O
duced,O
Social,O
Distancing,O
behavior,O
scenario,O
under,O
an,O
exponential,O
model,TITLE
until,O
herd,O
immunity,O
is,O
achieved,O
(,O
when,O
the,O
total,O
number,O
of,O
people,O
who,O
have,O
been,O
infected,O
and,O
recovered,O
),O
exceeds,O
65,PERCENT
%,PERCENT
of,O
the,O
population,O
),O
.,O
In,O
this,O
model,TITLE
.,O
herd,O
immunity,O
is,O
achieved,O
on,O
January,DATE
23,NUMBER
.,O
2021,DATE
.,O
The,O
herd,O
immunity,O
mortality,O
number,O
is,O
broadly,O
consis,O
‐,O
tent,O
with,O
pandemic,O
mortality,O
estimates,O
from,O
prior,O
models,O
.,O
(,O
6,NUMBER
),O
This,O
estimate,O
of,O
mortality,O
corresponds,O
to,O
a,O
infection,CAUSE_OF_DEATH
fatality,O
rate,O
estimates,O
.,O
(,O
7,NUMBER
.,O
8,NUMBER
),O
If,O
pandemic,O
mortality,O
can,O
be,O
reduced,O
through,O
al,O
‐,O
ternative,O
methods,O
of,O
achieving,O
herd,O
immunity,O
.,O
such,O
as,O
isolating,O
the,O
elderly,O
and,O
others,O
at,O
high,O
risk,O
from,O
COVID,O
‐,O
19,NUMBER
.,O
(,O
9,NUMBER
),O
then,O
the,O
partial,O
reopening,O
budget,O
goes,O
down,O
.,O
If,O
our,O
pandemic,O
mortality,O
is,O
an,O
underestimate,O
(,O
e.g.,O
due,O
to,O
ICU,O
overload,O
or,O
due,O
to,O
overshooting,O
of,O
herd,O
immunity,O
infection,CAUSE_OF_DEATH
rates,O
),O
.,O
(,O
10,NUMBER
),O
then,O
the,O
partial,O
reopening,O
budget,O
pandemic,O
mortality,O
and,O
the,O
partial,O
reopening,O
budget,O
(,O
see,O
appendix,O
A,O
),O
.,O
Benefits,O
of,O
a,O
partial,O
reopening,O
regime,O
.,O
COVID,O
‐,O
19,NUMBER
deaths,O
associated,O
with,O
continued,O
social,O
distancing,O
policies,O
are,O
obtained,O
from,O
the,O
Penn,ORGANIZATION
Wharton,ORGANIZATION
epidemiological,O
model,TITLE
(,O
5,NUMBER
),O
assump,O
‐,O
tions,O
as,O
of,O
May,DATE
26,DATE
.,DATE
2020,DATE
.,O
when,O
the,O
models,O
baseline,O
projections,O
accounted,O
for,O
the,O
maintenance,O
of,O
the,O
mortality,O
projections,O
from,O
this,O
model,TITLE
through,O
July,DATE
2020,DATE
and,O
assume,O
that,O
under,O
the,O
partial,O
reopening,O
occurring,O
as,O
of,O
end,DATE
of,DATE
May,DATE
2020,DATE
.,O
the,O
U.S.,COUNTRY
would,O
limit,O
additional,O
COVID,O
‐,O
19,NUMBER
deaths,O
to,O
26.285,NUMBER
per,O
month,DURATION
(,O
315.420,NUMBER
per,O
year,DURATION
),O
.,O
which,O
is,O
equal,O
to,O
the,O
average,O
monthly,SET
deaths,O
in,O
the,O
Penn,LOCATION
baseline,O
model,TITLE
from,O
May,DATE
26,DATE
.,DATE
2020,DATE
through,O
July,DATE
30,DATE
.,DATE
2020,DATE
.,O
In,O
our,O
extension,O
of,O
the,O
Penn,LOCATION
Wharton,CITY
model,TITLE
.,O
mortality,O
does,O
not,O
flatten,O
further,O
but,O
merely,O
continues,O
at,O
this,O
roughly,O
linear,O
pace,O
as,O
the,O
search,O
for,O
a,O
vaccine,O
or,O
therapeutic,O
continues,O
.,O
Maintaining,O
a,O
lim,O
‐,O
ited,O
reopening,O
policy,O
that,O
is,O
restricted,O
to,O
the,O
May,DATE
26,DATE
.,DATE
2020,DATE
lev,O
‐,O
el,O
over,O
the,DURATION
next,DURATION
12,DURATION
months,DURATION
therefore,O
saves,O
approximately,O
1.35,NUMBER
million,NUMBER
lives,O
relative,O
to,O
a,O
relatively,O
unrestrained,O
pandemic,O
end,O
‐,O
ing,O
in,O
herd,O
immunity,O
.,O
or,O
on,O
the,O
order,O
of,O
approximately,O
9.1,NUMBER
mil,O
‐,O
lion,O
quality,O
adjusted,O
life,O
‐,O
years,DURATION
saved,O
relative,O
to,O
full,O
reopen,O
‐,O
ing,O
.,O
If,O
a,O
vaccine,O
or,O
therapeutic,O
is,O
not,O
deployed,O
until,O
36,DURATION
months,DURATION
from,O
late,DATE
May,DATE
2020,DATE
.,O
maintaining,O
a,O
limited,O
reopening,O
would,O
save,O
718.000,NUMBER
lives,O
(,O
5.0,NUMBER
million,NUMBER
QALY,O
),O
.,O
These,O
QALY,O
estimate,O
reflect,O
the,O
age,O
‐,O
and,O
sex,O
‐,O
adjusted,O
lost,O
QALY,O
expectancy,O
of,O
COVID,O
‐,O
19,NUMBER
vic,O
‐,O
tims,O
.,O
If,O
true,O
mortality,O
from,O
an,O
alternative,O
herd,O
immunity,O
re,O
‐,O
sponse,O
is,O
substantially,O
higher,O
or,O
lower,O
than,O
this,O
modeled,O
esti,O
‐,O
mate,O
.,O
then,O
the,O
limited,O
reopening,O
budget,O
rises,O
or,O
falls,O
according,O
‐,O
ly,O
.,O
We,O
estimate,O
the,O
economic,O
value,O
of,O
the,O
quality,O
adjusted,O
life,O
years,DURATION
(,O
QALYs,O
),O
saved,O
$,MONEY
125.000,MONEY
and,O
a,O
discount,O
rate,O
of,O
3,PERCENT
%,PERCENT
(,O
standard,O
assumptions,O
),O
.,O
in,O
concert,O
with,O
Social,O
population,O
based,O
on,O
the,O
2010,DATE
Census,O
.,O
(,O
13,NUMBER
),O
plausible,O
age,O
and,O
sex,O
distributions,O
of,O
COVID,O
‐,O
19,NUMBER
mor,O
‐,O
tality,O
based,O
on,O
Centers,ORGANIZATION
for,ORGANIZATION
Disease,ORGANIZATION
Control,ORGANIZATION
and,ORGANIZATION
Prevention,ORGANIZATION
da,O
‐,O
ta,O
.,O
(,O
14,NUMBER
),O
and,O
estimates,O
of,O
quality,O
of,O
life,O
scores,O
from,O
previous,O
literature,O
.,O
(,O
15,NUMBER
),O
Alternative,O
values,O
for,O
a,O
Because,O
COVID,O
‐,O
19,NUMBER
mortal,O
‐,O
ity,O
is,O
skewed,O
toward,O
males,O
and,O
the,O
elderly,O
.,O
the,O
QALY,O
framework,O
reduces,O
the,O
economic,O
benefit,O
of,O
lives,O
saved,O
relative,O
to,O
using,O
a,O
fixed,O
statistical,O
value,O
per,O
life,O
and,O
therefore,O
shortens,O
the,O
lim,O
‐,O
ited,O
reopening,O
budget,O
relative,O
to,O
analyses,O
that,O
refer,O
only,O
to,O
mortality,O
totals,O
.,O
(,O
16,NUMBER
),O
We,O
do,O
not,O
adjust,O
for,O
reduced,O
QALY,O
from,O
COVID,O
‐,O
19,NUMBER
morbidity,O
among,O
those,O
who,O
recover,O
from,O
the,O
disease,CAUSE_OF_DEATH
(,O
which,O
would,O
lengthen,O
the,O
limited,O
reopening,O
budget,O
),O
or,O
from,O
re,O
‐,O
duced,O
QALY,O
expectancy,O
associated,O
with,O
preexisting,O
COVID,O
‐,O
19,NUMBER
risk,O
factors,O
and,O
comorbidities,O
such,O
as,O
obesity,O
.,O
hypertension,CAUSE_OF_DEATH
.,O
and,O
dia,O
‐,O
betes,O
(,O
which,O
would,O
shorten,O
the,O
limited,O
reopening,O
budget,O
),O
.,O
(,O
17,NUMBER
),O
Relative,O
to,O
shelter,O
‐,O
in,O
‐,O
place,O
restrictions,O
.,O
the,O
benefits,O
of,O
limit,O
‐,O
ed,O
reopening,O
are,O
economic,O
.,O
Following,O
the,O
Penn,LOCATION
‐,O
Wharton,O
model,TITLE
.,O
we,O
estimate,O
that,O
GDP,O
per,O
period,O
is,O
7.3,PERCENT
%,PERCENT
higher,O
year,DURATION
‐,O
on,O
‐,O
year,DURATION
under,O
limited,O
reopening,O
than,O
under,O
shelter,O
‐,O
in,O
‐,O
place,O
.,O
Costs,O
of,O
continu,O
‐,O
ing,O
a,O
partial,O
reopening,O
regime,O
We,O
rely,O
on,O
the,O
Penn,LOCATION
Wharton,CITY
inte,O
‐,O
grated,O
economic,O
and,O
epidemiological,O
model,TITLE
to,O
approximate,O
the,O
eco,O
‐,O
nomic,O
costs,O
of,O
a,O
limited,O
reopening,O
in,O
comparison,O
to,O
a,O
full,O
re,O
‐,O
opening,O
.,O
herd,O
immunity,O
strategy,O
.,O
(,O
5,NUMBER
),O
The,O
Penn,PERSON
Wharton,PERSON
model,TITLE
was,O
chosen,O
as,O
the,O
most,O
prominent,O
model,TITLE
of,O
which,O
we,O
are,O
aware,O
that,O
provides,O
both,O
mortality,O
estimates,O
and,O
year,DURATION
over,O
year,DURATION
effects,O
of,O
alternative,O
strategies,O
on,O
GDP,O
.,O
In,O
this,O
model,TITLE
.,O
maintaining,O
a,O
lim,O
‐,O
ited,O
reopening,O
(,O
baseline,O
policy,O
and,O
baseline,O
behavior,O
scenarios,O
in,O
the,O
Penn,LOCATION
Wharton,CITY
model,TITLE
as,O
of,O
May,DATE
26,DATE
.,DATE
2020,DATE
),O
reduces,O
GDP,O
by,O
4.3,PERCENT
%,PERCENT
measured,O
year,DURATION
‐,O
on,O
‐,O
year,DURATION
(,O
i.e.,O
May,DATE
2020,DATE
GDP,O
will,O
be,O
4.3,PERCENT
%,PERCENT
lower,O
than,O
May,DATE
2019,DATE
GDP,O
),O
.,O
Lesser,O
restrictions,O
(,O
full,O
reopening,O
policy,O
and,O
re,O
‐,O
duced,O
social,O
distancing,O
behavior,O
scenarios,O
),O
in,O
the,O
Penn,LOCATION
Wharton,CITY
model,TITLE
are,O
associated,O
with,O
an,O
increase,O
in,O
GDP,O
of,O
1.4,PERCENT
%,PERCENT
year,DURATION
on,O
year,DURATION
.,O
an,O
absolute,O
decrease,O
of,O
0.8,PERCENT
%,PERCENT
from,O
the,O
Congressional,ORGANIZATION
Budget,ORGANIZATION
Offices,O
pre,O
‐,O
COVID,O
projections,O
of,O
2.2,PERCENT
%,PERCENT
growth,O
.,O
(,O
18,NUMBER
),O
Of,O
note,O
.,O
the,O
Penn,PERSON
Wharton,PERSON
model,TITLE
attributes,O
less,O
economic,O
importance,O
to,O
indi,O
‐,O
vidual,O
behavioral,O
changes,O
that,O
are,O
independent,RELIGION
of,O
official,O
pro,O
‐,O
nouncements,O
than,O
prior,O
modeling,O
of,O
the,O
economic,O
effects,O
of,O
pan,O
‐,O
demics,O
.,O
(,O
18,NUMBER
‐,O
20,NUMBER
),O
All,O
GDP,O
calculations,O
are,O
discounted,O
at,O
3,PERCENT
%,PERCENT
annually,SET
in,O
our,O
calculations,O
in,O
parallel,O
with,O
QALY,O
discounting,O
.,O
Alterna,O
‐,O
tive,O
assumptions,O
regarding,O
the,O
GDP,O
cost,O
of,O
limited,O
reopening,O
on,O
GDP,O
are,O
Following,O
the,O
hypothetical,O
achievement,O
of,O
herd,O
immunity,O
at,O
65,PERCENT
%,PERCENT
of,O
the,O
population,O
recovered,O
from,O
infection,CAUSE_OF_DEATH
as,O
of,O
January,DATE
23,NUMBER
.,O
2021,DATE
.,O
we,O
assume,O
that,O
the,O
Penn,O
Wharton,O
projection,O
of,O
GDP,O
ef,O
‐,O
fects,O
slowly,O
improves,O
.,O
returning,O
to,O
2019,DATE
levels,O
of,O
2.2,PERCENT
%,PERCENT
growth,O
three,DURATION
months,DURATION
after,O
the,O
pandemic,O
ends,O
as,O
economic,O
uncertainty,O
re,O
‐,O
solves,O
and,O
activity,O
restrictions,O
and,O
voluntary,O
social,O
distancing,O
slowly,O
end,O
.,O
A,O
longer,O
or,O
shorter,O
period,O
of,O
time,O
prior,O
to,O
achieve,O
‐,O
ment,O
of,O
herd,O
immunity,O
and,O
its,O
effects,O
on,O
our,O
partial,O
We,O
assume,O
that,O
non,O
‐,O
economic,O
costs,O
associated,O
with,O
partial,O
reopening,O
are,O
$,MONEY
0,MONEY
.,O
For,O
example,O
.,O
our,O
model,TITLE
includes,O
no,O
cost,O
if,O
educators,O
are,O
paid,O
and,O
students,O
attend,O
costs,O
such,O
as,O
the,O
value,O
of,O
lost,O
learning,O
.,O
(,O
21,NUMBER
),O
would,O
reduce,O
the,O
length,O
of,O
the,O
limited,O
reopening,O
budget,O
across,O
a,O
variety,O
of,O
GDP,O
costs,O
.,O
Relative,O
to,O
a,O
shelter,O
‐,O
in,O
‐,O
place,O
strategy,O
.,O
limited,O
reopening,O
is,O
associated,O
with,O
higher,O
mortality,O
.,O
The,O
cost,O
of,O
limited,O
reopening,O
relative,O
to,O
shelter,O
‐,O
in,O
‐,O
place,O
is,O
the,O
value,O
assigned,O
to,O
the,O
QALYs,O
saved,O
by,O
shelter,O
‐,O
in,O
‐,O
place,O
.,O
Our,O
shelter,O
‐,O
in,O
‐,O
place,O
threshold,O
provides,O
the,O
number,O
of,O
lives,O
that,O
must,O
be,O
saved,O
by,O
a,DURATION
month,DURATION
of,O
shelter,O
in,O
place,O
relative,O
to,O
limited,O
reopening,O
to,O
justify,O
returning,O
to,O
shelter,O
‐,O
in,O
‐,O
place,O
.,O
If,O
shelter,O
‐,O
in,O
‐,O
place,O
re,O
‐,O
strictions,O
do,O
not,O
avoid,O
fatalities,O
but,O
rather,O
delay,O
them,O
to,O
later,O
periods,O
.,O
then,O
these,O
delayed,O
fatalities,O
are,O
not,O
included,O
in,O
the,O
shelter,O
‐,O
in,O
‐,O
place,O
threshold,O
.,O
Instead,O
.,O
an,O
additional,O
month,DURATION
of,O
shel,O
‐,O
ter,TITLE
‐,O
inplace,O
needs,O
to,O
save,O
at,O
least,O
the,O
threshold,O
number,O
of,O
lives,O
until,O
the,O
deployment,O
of,O
an,O
effective,O
vaccine,O
or,O
therapeutic,O
.,O
Our,O
simulation,O
assumes,O
there,O
is,O
no,O
difference,O
in,O
non,O
‐,O
COVID,O
‐,O
19,NUMBER
deaths,O
between,O
the,O
pandemic,O
scenario,O
and,O
the,O
limited,O
reopening,O
scenario,O
.,O
so,O
long,O
as,O
all,O
deaths,O
from,O
COVID,O
‐,O
19,NUMBER
are,O
properly,O
counted,O
.,O
We,O
rec,O
‐,O
ognize,O
that,O
the,O
pandemic,O
is,O
causing,O
nonCOVID,O
‐,O
19,NUMBER
mortality,O
to,O
rise,O
substantially,O
due,O
to,O
both,O
a,O
lack,O
of,O
hospital,O
treatment,O
capacity,O
and,O
avoidance,O
and,O
delay,O
of,O
medical,O
care,O
.,O
Because,O
the,O
pandemic,O
spreads,O
relatively,O
slowly,O
even,O
under,O
full,O
reopening,O
with,O
reduced,O
social,O
distancing,O
in,O
the,O
Penn,LOCATION
Wharton,CITY
model,TITLE
.,O
the,O
danger,O
of,O
over,O
‐,O
whelming,O
hospitals,O
appears,O
lower,O
than,O
earlier,O
fears,O
.,O
With,O
respect,O
to,O
avoidance,O
and,O
delay,O
of,O
medical,O
care,O
.,O
the,O
pandemic,O
ends,O
within,O
8,DURATION
months,DURATION
.,O
After,O
this,O
point,O
.,O
we,O
assume,O
that,O
patients,O
access,O
medi,O
‐,O
cal,O
care,O
at,O
normal,O
rates,O
.,O
If,O
the,O
wait,O
for,O
a,O
widely,O
available,O
vac,O
‐,O
cine,O
takes,O
longer,O
than,O
8,DURATION
months,DURATION
.,O
limited,O
reopening,O
may,O
therefore,O
be,O
associated,O
with,O
more,O
avoidance,O
and,O
delay,O
of,O
care,O
than,O
a,O
pan,O
‐,O
demic,O
.,O
Rather,O
than,O
making,O
an,O
uninformed,O
guess,O
about,O
the,O
size,O
of,O
these,O
effects,O
.,O
we,O
allow,O
fact,O
higher,O
from,O
ICU,O
overload,O
or,O
other,O
effects,O
in,O
the,O
pandemic,O
scenario,O
.,O
then,O
the,O
limited,O
reopening,O
bud,O
‐,O
get,O
reported,O
above,O
should,O
be,O
longer,O
.,O
COVID,O
‐,O
19,NUMBER
presents,O
horrific,O
policy,O
choices,O
.,O
The,O
restrictions,O
necessary,O
to,O
avoid,O
unprecedented,O
disease,CAUSE_OF_DEATH
mortality,O
impose,O
unprecedented,O
economic,O
calamity,O
.,O
Our,O
cost,O
benefit,O
analysis,O
attempts,O
to,O
compare,O
these,O
factors,O
using,O
a,O
widely,O
used,O
framework,O
.,O
Given,O
current,DATE
expectations,O
about,O
future,DATE
vaccine,O
availability,O
.,O
we,O
conclude,O
that,O
maintaining,O
limited,O
re,O
‐,O
opening,O
with,O
social,O
distancing,O
to,O
the,O
levels,O
present,DATE
on,O
May,DATE
26,DATE
.,O
2020,DATE
demonstrates,O
cost,O
effectiveness,O
relative,O
to,O
both,O
a,O
policy,O
of,O
shelter,O
in,O
place,O
and,O
a,O
policy,O
of,O
full,O
reopening,O
toward,O
herd,O
immu,O
‐,O
nity,O
.,O
As,O
additional,O
information,O
on,O
a,O
vaccine,O
timeline,O
.,O
the,O
non,O
‐,O
economic,O
costs,O
of,O
partial,O
reopening,O
.,O
and,O
the,O
potential,O
increase,O
in,O
mortality,O
due,O
to,O
ICU,O
overload,O
in,O
a,O
relatively,O
unrestrained,O
pandemic,O
become,O
available,O
.,O
effect,O
of,O
these,O
tradeoffs,O
as,O
new,O
in,O
‐,O
formation,O
appears,O
.,O
We,O
estimate,O
that,O
shelter,O
in,O
place,O
restric,O
‐,O
tions,O
need,O
to,O
prevent,O
at,O
least,O
154.586,NUMBER
COVID,O
‐,O
19,NUMBER
deaths,O
for,O
each,O
month,DURATION
they,O
are,O
in,O
effect,O
to,O
demonstrate,O
cost,O
effectiveness,O
rela,O
‐,O
tive,O
to,O
limited,O
reopening,O
.,O
a,O
threshold,O
which,O
is,O
unlikely,O
to,O
be,O
met,O
.,O
While,O
readers,O
may,O
experience,O
this,O
calculus,O
favoring,O
a,O
limit,O
‐,O
ed,O
reopening,O
over,O
a,O
return,O
to,O
shelter,O
in,O
place,O
as,O
unduly,O
grisly,O
.,O
we,O
would,O
suggest,O
that,O
the,O
healthcare,O
community,O
.,O
focused,O
on,O
pa,O
‐,O
tient,O
care,O
.,O
may,O
(,O
understandably,O
),O
skew,O
toward,O
a,O
perspective,O
that,O
emphasizes,O
the,O
costs,O
of,O
lives,O
lost,O
to,O
disease,CAUSE_OF_DEATH
over,O
the,O
costs,O
of,O
unemployment,O
rivaling,O
the,O
Great,O
Depression,O
and,O
dislocated,O
family,O
and,O
educational,O
lives,O
.,O
However,O
.,O
the,O
disparities,O
in,O
how,O
the,O
socio,O
‐,O
economic,O
burden,O
is,O
imposed,O
upon,O
the,O
most,O
disadvantaged,O
relative,O
to,O
the,O
well,O
‐,O
off,O
may,O
be,O
even,O
community,O
is,O
so,O
familiar,O
.,O
11.1,NUMBER
months,DURATION
(,O
or,O
a,O
revised,O
estimate,O
derived,O
from,O
different,O
assumptions,O
),O
is,O
our,O
limited,O
reopening,O
budget,O
for,O
mitigating,O
COVID,O
‐,O
19,NUMBER
.,O
The,O
lim,O
‐,O
ited,O
reopening,O
budget,O
means,O
that,O
if,O
we,O
think,O
.,O
as,O
of,O
the,O
end,O
of,O
May,DATE
2020,DATE
.,O
that,O
we,O
can,O
implement,O
an,O
effective,O
COVID,O
‐,O
19,NUMBER
therapy,O
or,O
vaccine,O
within,O
11.1,DURATION
months,DURATION
.,O
as,O
the,O
White,ORGANIZATION
House,ORGANIZATION
has,O
publicly,O
pro,O
‐,O
claimed,O
.,O
then,O
we,O
should,O
pursue,O
a,O
coordinated,O
national,O
strategy,O
to,O
maintain,O
a,O
limited,O
reopening,O
at,O
the,O
levels,O
in,O
place,O
as,O
of,O
May,DATE
26,DATE
.,O
2020,DATE
.,O
and,O
accept,O
the,O
grievous,O
economic,O
consequences,O
.,O
Alternative,O
‐,O
ly,O
.,O
if,O
we,O
find,O
ourselves,O
unsure,O
regarding,O
treatment,O
and,O
push,O
off,O
both,O
the,O
large,O
short,O
‐,O
term,O
mortality,O
costs,O
of,O
full,O
reopening,O
and,O
the,O
economic,O
costs,O
of,O
shelter,O
‐,O
in,O
‐,O
place,O
restrictions,O
.,O
If,O
we,O
expect,O
the,O
waiting,O
period,O
to,O
resolve,O
the,O
and,O
economic,O
harm,O
.,O
(,O
22,NUMBER
),O
If,O
in,O
‐,O
stead,O
we,O
conclude,O
that,O
these,O
scenarios,O
are,O
wishful,O
thinking,O
and,O
we,O
face,O
an,O
expected,O
wait,O
time,O
longer,O
than,O
11.1,DURATION
months,DURATION
.,O
then,O
we,O
should,O
develop,O
the,O
most,O
effective,O
herd,O
immunity,O
strategy,O
we,O
can,O
(,O
such,O
as,O
concentrating,O
infection,CAUSE_OF_DEATH
among,O
those,O
below,O
age,O
50,NUMBER
),O
and,O
implement,O
it,O
to,O
minimize,O
economic,O
devastation,O
and,O
loss,O
of,O
life,O
.,O
Picking,O
any,O
one,NUMBER
of,O
these,O
devastating,O
health,O
and,O
economic,O
choices,O
is,O
.,O
and,O
should,O
be,O
.,O
repellent,O
.,O
but,O
such,O
is,O
the,O
dilemma,O
presented,O
by,O
COVID,O
‐,O
19,NUMBER
.,O
Boardman,PERSON
A,O
.,O
Greenberg,PERSON
D,O
.,O
Vining,O
A,O
.,O
Weimer,O
D.,O
Cost,O
‐,O
Benefit,O
Analysis,O
:,O
Husereau,PERSON
D,PERSON
.,O
Drummond,PERSON
M,O
.,O
Petrou,PERSON
S,O
.,O
al,O
.,O
E.,O
Con,O
‐,O
solidated,O
health,O
economic,O
evaluation,O
reporting,O
standards,O
(,O
CHEERS,O
),O
‐,O
explanation,O
and,O
elaboration,O
:,O
a,O
report,O
of,O
the,O
ISPOR,O
Health,O
Eco,O
‐,O
nomic,O
Evaluations,O
Publication,O
Guidelines,O
Good,O
Reporting,O
Practices,O
Task,O
Force,O
.,O
Value,ORGANIZATION
Health,ORGANIZATION
.,O
2013,DATE
;,O
16,NUMBER
(,O
2,NUMBER
),O
:,O
231,NUMBER
‐,O
50,NUMBER
.,O
Thunstrm,O
L,O
.,O
Newbold,PERSON
SC,STATE_OR_PROVINCE
.,O
Finnoff,O
D,O
.,O
Ashworth,PERSON
M,O
.,O
Shogren,PERSON
JF,O
.,O
The,O
Benefits,O
of,O
Benefit,O
‐,O
Cost,O
Analysis,O
.,O
2020:1,NUMBER
‐,O
17,NUMBER
.,O
and,O
Economic,O
Effects,O
of,O
State,O
Reopen,O
‐,O
ings,O
;,O
url,O
:,O
Ferguson,ORGANIZATION
NM,ORGANIZATION
.,O
Laydon,PERSON
D,O
.,O
Nedjati,O
‐,O
Gilani,PERSON
G,PERSON
.,O
Natsuko,PERSON
I,O
.,O
Ainslie,PERSON
K,PERSON
.,O
Baguelin,PERSON
M,O
.,O
et,O
al,O
.,O
Impact,O
of,O
non,O
‐,O
pharmaceutical,O
inter,O
‐,O
ventions,O
(,O
NPIs,O
),O
to,O
reduce,O
COVID,O
‐,O
19,NUMBER
college,O
/,O
medicine,O
/,O
sph,O
/,O
ide,O
/,O
gi,O
‐,O
da,O
‐,O
fellowships,O
/,O
Imperial,O
‐,O
College,O
‐,O
COVID19,O
‐,O
NPImod,O
‐,O
elling,O
‐,O
16,NUMBER
‐,O
03,NUMBER
‐,O
2020.pdf,NUMBER
as,O
accessed,O
March,DATE
23,DATE
.,DATE
2020,DATE
.,O
Russell,PERSON
TW,PERSON
.,O
Hellewell,PERSON
J,PERSON
.,O
Jarvis,PERSON
CI,PERSON
.,O
van,O
Zandvoort,CITY
K,LOCATION
.,O
Abbott,PERSON
S,O
.,O
Ratnayake,PERSON
R,PERSON
.,O
et,O
al,O
.,O
Estimating,O
the,O
infection,CAUSE_OF_DEATH
and,O
case,O
fatality,O
ratio,O
for,O
coro,O
‐,O
navirus,O
disease,CAUSE_OF_DEATH
(,O
COVID,O
‐,O
19,NUMBER
),O
using,O
age,O
‐,O
adjusted,O
data,O
from,O
the,O
out,O
‐,O
break,O
on,O
the,O
Diamond,MISC
Princess,TITLE
cruise,O
ship,O
.,O
February,DATE
2020,DATE
.,O
Euro,O
Surveill,O
.,O
2020,DATE
;,O
25,NUMBER
(,O
12,NUMBER
),O
.,O
Verity,ORGANIZATION
R,ORGANIZATION
.,O
Okell,ORGANIZATION
LC,ORGANIZATION
.,O
Dorigatti,PERSON
I,O
.,O
Winskill,PERSON
P,O
.,O
Whittaker,PERSON
C,O
.,O
Imai,PERSON
N,O
.,O
et,O
al,O
.,O
Estimates,O
of,O
the,O
severity,O
of,O
coro,O
‐,O
navirus,O
disease,CAUSE_OF_DEATH
2019,DATE
:,O
a,O
model,TITLE
‐,O
based,O
analysis,O
.,O
The,O
Lancet,O
Infec,O
‐,O
tious,O
Diseases,CAUSE_OF_DEATH
.,O
2020,DATE
.,O
Acemoglu,PERSON
D,O
.,O
Chernozhukov,PERSON
V,PERSON
.,O
Werning,PERSON
I,O
.,O
Whinston,PERSON
MD,O
.,O
A,O
Multi,O
‐,O
Risk,O
SIR,O
Model,TITLE
with,O
Optimally,O
Targeted,O
Lock,O
‐,O
down,O
;,O
National,ORGANIZATION
Bureau,ORGANIZATION
of,ORGANIZATION
Economic,ORGANIZATION
Research,ORGANIZATION
;,O
No,O
.,O
Bergstrom,ORGANIZATION
CT,ORGANIZATION
.,O
Dean,TITLE
N,O
.,O
What,O
the,O
Proponents,O
of,O
’,O
Natural,O
’,O
Herd,O
Immunity,O
Do,O
n’t,O
Say,O
;,O
New,ORGANIZATION
York,ORGANIZATION
Times,ORGANIZATION
;,O
May,DATE
1,DATE
.,DATE
2020,DATE
;,O
url,O
:,O
Weiss,PERSON
RD,O
.,O
Potter,ORGANIZATION
JS,ORGANIZATION
.,O
Griffin,PERSON
ML,O
.,O
Provost,O
SE,O
.,O
Fitzmaurice,ORGANIZATION
GM,ORGANIZATION
.,O
McDermott,ORGANIZATION
KA,ORGANIZATION
.,O
et,O
al,O
.,O
Long,O
‐,O
term,O
outcomes,O
from,O
the,O
National,O
Drug,O
Abuse,O
Treatment,O
Clinical,O
Trials,O
Network,O
Prescription,O
Opioid,O
Addiction,O
Treatment,O
Study,O
.,O
Drug,O
&,O
Al,O
‐,O
cohol,O
Howden,ORGANIZATION
JM,ORGANIZATION
.,O
Meyer,PERSON
JA,O
.,O
Census,O
Briefs,O
:,O
Age,O
and,O
Sex,O
Composi,O
‐,O
tion,O
:,O
2010,DATE
;,O
United,ORGANIZATION
States,ORGANIZATION
Census,ORGANIZATION
Bureau,ORGANIZATION
;,O
US,ORGANIZATION
Department,ORGANIZATION
of,ORGANIZATION
Com,ORGANIZATION
‐,O
merce,O
(,O
2011,DATE
May,DATE
),O
;,O
url,O
:,O
Coronavirus,O
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
Surveillance,O
Data,O
;,O
National,ORGANIZATION
Vital,ORGANIZATION
Statistics,ORGANIZATION
System,ORGANIZATION
.,O
National,ORGANIZATION
Center,ORGANIZATION
for,O
Health,O
Statistics,O
.,O
url,O
:,O
Claxton,PERSON
K,PERSON
.,O
Martin,PERSON
S,PERSON
.,O
Soares,PERSON
M,O
.,O
al,O
.,O
E.,O
Methods,O
for,O
the,O
estimation,O
of,O
the,O
National,O
Assessment,O
.,O
No,O
.,O
19.14,NUMBER
.,O
),O
Appendix,O
3,NUMBER
.,O
Translating,O
mortality,O
effects,O
into,O
life,O
‐,O
years,DURATION
and,O
quality,O
‐,O
adjusted,O
life,O
‐,O
years,DURATION
;,O
url,O
:,O
Hammitt,PERSON
JK,O
.,O
QALYs,O
Versus,O
WTP,O
.,O
Risk,O
Analysis,O
.,O
2002,DATE
;,O
22,NUMBER
(,O
5,NUMBER
),O
:,O
985,NUMBER
‐,O
1001,DATE
.,O
Richardson,PERSON
S,O
.,O
Hirsch,PERSON
JS,O
.,O
Narasimhan,PERSON
M,O
.,O
Crawford,ORGANIZATION
JM,ORGANIZATION
.,O
McGinn,PERSON
T,O
.,O
Davidson,ORGANIZATION
KW,ORGANIZATION
.,O
et,O
al,O
.,O
Pre,O
‐,O
senting,O
Characteristics,MISC
.,O
Comorbidities,O
.,O
and,O
Outcomes,O
Among,O
5700,NUMBER
Patients,O
Hospitalized,O
With,O
COVID,O
‐,O
19,NUMBER
in,O
the,O
New,CITY
York,CITY
City,CITY
Area,LOCATION
.,O
JAMA,ORGANIZATION
.,O
2020,DATE
.,O
Keogh,PERSON
‐,O
Brown,O
MR.,O
The,O
possible,O
macroeconomic,O
impact,O
on,O
the,O
UK,COUNTRY
of,O
an,O
influenza,CAUSE_OF_DEATH
pandemic,O
.,O
Health,O
economics,O
.,O
2010,DATE
;,O
19,NUMBER
(,O
11,NUMBER
),O
:,O
1345,DATE
‐,O
60,NUMBER
.,O
Dandekar,PERSON
R,PERSON
.,O
G.,PERSON
B.,PERSON
Quantifying,PERSON
the,O
effect,O
of,O
quarantine,O
control,O
in,O
Covid,O
‐,O
19,NUMBER
infectious,O
spread,O
using,O
machine,O
learning,O
;,O
medRxiv,O
;,O
url,O
:,O
Friedson,PERSON
AI,O
.,O
McNichols,ORGANIZATION
D,O
.,O
Sabia,PERSON
JJ,PERSON
.,O
Dave,PERSON
D,O
.,O
Did,O
Californias,O
Shelter,O
‐,O
in,O
‐,O
Place,O
Order,O
Work,O
?,O
Early,O
Coron,O
‐,O
avirus,O
‐,O
Related,ORGANIZATION
Public,ORGANIZATION
Health,ORGANIZATION
Effects,ORGANIZATION
;,O
National,ORGANIZATION
Bureau,ORGANIZATION
of,ORGANIZATION
Economic,ORGANIZATION
Research,O
Working,O
Paper,O
Series,O
:,O
No.,O
26992,NUMBER
;,O
url,O
:,O
Soland,PERSON
J,PERSON
.,O
Kuhfeld,PERSON
M,O
.,O
Tarasawa,PERSON
B,PERSON
.,O
Johnson,PERSON
A,O
.,O
Ruzek,PERSON
E,O
.,O
Liu,PERSON
J,PERSON
.,O
The,O
Impact,O
of,O
COVID,O
‐,O
19,NUMBER
on,O
student,TITLE
achievement,O
and,O
what,O
it,O
may,O
mean,O
for,O
educators,O
;,O
Brown,PERSON
Center,O
Chalkboard,O
;,O
Brookings,ORGANIZATION
Insitute,ORGANIZATION
;,O
May,DATE
27,DATE
.,DATE
2020,DATE
.,O
Ayres,PERSON
I,O
.,O
Listokin,PERSON
YJ,PERSON
.,O
Schonberger,PERSON
RB,O
.,O
The,O
Option,O
Preserving,O
Value,O
of,O
So,O
‐,O
cial,O
Distancing,O
;,O
Incidental,O
Economist,TITLE
.,O
url,O
:,O
List,O
of,O
Assumptions,O
Quality,O
‐,O
Adjusted,O
Life,O
Year,DURATION
Value,O
Input,O
Value,O
Discount,O
rate,O
on,O
QALYs,O
for,O
present,DATE
value,O
[,O
2,NUMBER
],O
Unmitigated,O
Scenario,O
Deaths,O
COVID,O
‐,O
19,NUMBER
deaths,O
as,O
of,O
projection,O
date,O
Present,DATE
Scenario,O
:,O
Additional,O
COVID,O
‐,O
19,NUMBER
deaths,O
per,O
month,DURATION
policy,O
is,O
in,O
place,O
[,O
5,NUMBER
],O
Additional,O
non,O
‐,O
COVID,O
‐,O
19,NUMBER
deaths,O
(,O
due,O
to,O
system,O
overload,O
or,O
avoidance,O
),O
in,O
unmiti,O
‐,O
gated,O
scenario,O
[,O
6,NUMBER
],O
Additional,O
non,O
‐,O
COVID,O
‐,O
19,NUMBER
deaths,O
(,O
due,O
to,O
system,O
overload,O
or,O
avoidance,O
),O
in,O
suppression,O
scenario,O
[,O
6,NUMBER
],O
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Male,O
.,O
Under,O
1,DURATION
year,DURATION
[,O
7,NUMBER
],O
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Male,O
.,O
1,NUMBER
‐,O
4,DURATION
years,DURATION
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Male,O
.,O
5,NUMBER
‐,O
14,DURATION
years,DURATION
[,O
7,NUMBER
],O
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Male,O
.,O
25,NUMBER
‐,O
34,NUMBER
years,DURATION
[,O
7,NUMBER
],O
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Male,O
.,O
45,NUMBER
‐,O
54,DURATION
years,DURATION
[,O
7,NUMBER
],O
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Male,O
.,O
15,NUMBER
‐,O
24,DURATION
years,DURATION
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Male,O
.,O
35,NUMBER
‐,O
44,DURATION
years,DURATION
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mor,O
‐,O
talities,O
.,O
Male,O
.,O
55,NUMBER
‐,O
64,DURATION
years,DURATION
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Male,O
.,O
65,NUMBER
‐,O
74,DURATION
years,DURATION
[,O
7,NUMBER
],O
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Male,O
.,O
75,NUMBER
‐,O
84,DURATION
years,DURATION
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Male,O
.,O
85,DURATION
years,DURATION
and,O
over,O
[,O
7,NUMBER
],O
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Female,O
.,O
Under,O
1,DURATION
year,DURATION
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Female,O
.,O
1,NUMBER
‐,O
4,DURATION
years,DURATION
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Female,O
.,O
5,NUMBER
‐,O
14,DURATION
years,DURATION
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Female,O
.,O
15,NUMBER
‐,O
24,DURATION
years,DURATION
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortali,O
‐,O
ties,O
.,O
Female,O
.,O
25,NUMBER
‐,O
34,DURATION
years,DURATION
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Fe,O
‐,O
male,O
.,O
35,NUMBER
‐,O
44,DURATION
years,DURATION
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Female,O
.,O
45,NUMBER
‐,O
54,NUMBER
years,DURATION
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Female,O
.,O
55,NUMBER
‐,O
64,DURATION
years,DURATION
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Female,O
.,O
65,NUMBER
‐,O
74,DURATION
years,DURATION
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Female,O
.,O
75,NUMBER
‐,O
84,DURATION
years,DURATION
[,O
7,NUMBER
],O
Share,O
of,O
US,COUNTRY
COVID,O
‐,O
19,NUMBER
mortalities,O
.,O
Female,O
.,O
85,DURATION
years,DURATION
and,O
over,O
Average,O
per,O
period,O
change,O
in,O
GDP,O
under,O
shelter,O
‐,O
in,O
‐,O
place,O
[,O
8,NUMBER
],O
Average,O
per,O
period,O
change,O
in,O
GDP,O
under,O
current,DATE
scenario,O
[,O
9,NUMBER
],O
Average,O
per,O
period,O
change,O
in,O
GDP,O
under,O
unmitigated,O
scenario,O
prior,O
to,O
herd,O
Expected,O
per,O
period,O
change,O
in,O
GDP,O
without,O
COVID,O
‐,O
19,NUMBER
[,O
11,NUMBER
],O
Months,DURATION
before,O
herd,O
immunity,O
achieved,O
un,O
‐,O
der,O
unmitigated,O
scenario,O
[,O
12,NUMBER
],O
Months,DURATION
between,O
herd,O
immunity,O
and,O
GDP,O
stabilizing,O
US,COUNTRY
GDP,O
(,O
trillion,NUMBER
USD,O
),O
US,COUNTRY
Population,O
Share,O
of,O
Popula,O
‐,O
tion,O
Infected,O
and,O
Recovered,O
to,O
Reach,O
Herd,O
Immunity,O
Share,O
of,O
Popu,O
‐,O
lation,O
By,O
Year,DURATION
of,O
Age,O
and,O
Sex,O
[,O
14,NUMBER
],O
Population,O
Baseline,O
Probability,O
of,O
Death,MISC
By,MISC
Year,DURATION
of,MISC
Age,MISC
and,O
Sex,O
[,O
15,NUMBER
],O
Quality,O
of,O
Life,O
Adjustments,O
By,O
Year,DURATION
of,O
Age,O
and,O
Sex,O
[,O
16,NUMBER
],O
[,O
1,NUMBER
],O
ICER,ORGANIZATION
guidelines,O
suggest,O
a,O
value,O
of,O
$,MONEY
100.000,MONEY
‐,O
$,MONEY
150.000,MONEY
per,O
QALY,O
.,O
Our,O
estimates,O
use,O
the,O
midpoint,O
of,O
this,O
range,O
.,O
[,O
2,NUMBER
],O
ICER,ORGANIZATION
guidelines,O
dictate,O
that,O
QALYs,O
are,O
put,O
into,O
present,DATE
value,O
with,O
a,O
3,PERCENT
%,PERCENT
discount,O
rate,O
which,O
we,O
also,O
apply,O
to,O
fu,O
‐,O
ture,O
GDP,O
costs,O
.,O
Of,O
note,O
.,O
we,O
further,O
apply,O
3,PERCENT
%,PERCENT
annual,SET
discounting,O
for,O
mortality,O
incurred,O
during,O
both,O
the,O
limited,O
reopening,O
and,O
full,O
reopening,O
scenarios,O
.,O
with,O
the,O
simplifying,O
assumption,O
that,O
an,O
ad,O
‐,O
justment,O
for,O
discounting,O
is,O
applied,O
to,O
future,DATE
deaths,O
assuming,O
a,O
uniform,O
distribution,O
of,O
deaths,O
.,O
Within,O
the,O
degree,O
of,O
precision,O
appropriate,O
for,O
the,O
present,DATE
model,TITLE
.,O
this,O
discounting,O
would,O
result,O
in,O
some,O
deaths,O
being,O
discounted,O
too,O
much,O
and,O
others,O
not,O
enough,O
.,O
but,O
the,O
effects,O
are,O
roughly,O
cancelled,O
out,O
.,O
[,O
3,NUMBER
],O
Based,O
on,O
trend,O
from,O
the,O
Penn,LOCATION
COVID,O
‐,O
19,NUMBER
model,TITLE
projected,O
out,O
until,O
the,O
country,O
achieves,O
herd,O
immunity,O
in,O
July,DATE
due,O
to,O
the,O
large,O
volume,O
of,O
infec,O
‐,O
tions,O
.,O
[,O
4,NUMBER
],O
Estimates,O
are,O
sourced,O
from,O
the,O
Penn,O
Wharton,O
COVID,O
‐,O
19,NUMBER
model,TITLE
.,O
[,O
5,NUMBER
],O
We,O
assume,O
that,O
deaths,O
continue,O
to,O
increase,O
at,O
the,O
av,O
‐,O
erage,O
daily,SET
rate,O
projected,O
from,O
May,DATE
19th,DATE
through,DATE
July,DATE
24th,DATE
in,O
the,O
Penn,PERSON
Wharton,PERSON
COVID,O
‐,O
19,NUMBER
model,TITLE
(,O
which,O
projects,O
an,O
approximately,O
lin,O
‐,O
ear,O
increase,O
in,O
deaths,O
over,O
that,O
period,O
),O
.,O
[,O
6,NUMBER
],O
It,O
is,O
unclear,O
whether,O
there,O
would,O
be,O
greater,O
non,O
‐,O
COVID,O
‐,O
19,NUMBER
mortality,O
(,O
due,O
to,O
ei,O
‐,O
ther,O
health,O
care,O
system,O
overload,O
or,O
avoidance,O
),O
in,O
an,O
unmitigated,O
pandemic,O
or,O
under,O
a,O
policy,O
intervention,O
.,O
Due,O
to,O
this,O
.,O
we,O
assume,O
non,O
‐,O
COVID,O
‐,O
19,NUMBER
deaths,O
in,O
both,O
scenarios,O
are,O
equal,O
to,O
zero,NUMBER
so,O
that,O
the,O
difference,O
between,O
the,O
two,NUMBER
estimates,O
interactive,O
calcula,O
‐,O
tions,O
.,O
[,O
7,NUMBER
],O
Sourced,O
from,O
NCHS,ORGANIZATION
provisional,O
COVID,O
‐,O
19,NUMBER
death,O
esti,O
‐,O
mates,O
by,O
gender,O
and,O
age,O
from,O
2/1/2020,DATE
5/16/2020,DATE
.,O
with,O
data,O
as,O
of,O
5/20/2020,DATE
.,O
[,O
8,NUMBER
],O
Sourced,O
from,O
Penn,PERSON
Wharton,PERSON
COVID,O
‐,O
19,NUMBER
model,TITLE
baseline,O
policy,O
and,O
baseline,O
social,O
distancing,O
model,TITLE
as,O
of,O
May,DATE
4,DATE
.,DATE
2020,DATE
(,O
prior,O
to,O
nearly,O
all,O
state,O
reopenings,O
),O
.,O
[,O
9,NUMBER
],O
Sourced,O
from,O
Penn,LOCATION
Wharton,O
COVID,O
‐,O
19,NUMBER
model,TITLE
baseline,O
policy,O
and,O
baseline,O
social,O
dis,O
‐,O
tancing,O
model,TITLE
as,O
of,O
May,DATE
26,DATE
.,DATE
2020,DATE
.,O
[,O
10,NUMBER
],O
Sourced,O
from,O
Penn,LOCATION
Wharton,CITY
COVID,O
‐,O
19,NUMBER
model,TITLE
full,O
reopening,O
and,O
reduced,O
social,O
distancing,O
model,TITLE
as,O
of,O
May,DATE
26,DATE
.,DATE
2020,DATE
.,O
[,O
11,NUMBER
],O
Sourced,O
from,O
CBO,ORGANIZATION
economic,O
outlook,O
pro,O
‐,O
jections,O
from,O
January,DATE
2020,DATE
.,O
[,O
12,NUMBER
],O
Based,O
on,O
projecting,O
out,O
the,O
Penn,PERSON
Wharton,PERSON
COVID,O
‐,O
19,NUMBER
model,TITLE
until,O
herd,O
immunity,O
is,O
reached,O
and,O
65,PERCENT
%,PERCENT
of,O
the,O
population,O
has,O
been,O
infected,O
.,O
We,O
assume,O
that,O
cases,O
in,O
‐,O
crease,O
at,O
an,O
exponential,O
rate,O
fom,O
the,O
final,O
date,O
of,O
the,O
Penn,LOCATION
Wharton,O
COVID,O
‐,O
19,NUMBER
model,TITLE
projections,O
(,O
July,DATE
30,DATE
.,DATE
2020,DATE
),O
until,O
more,O
than,O
32.5,PERCENT
%,PERCENT
of,O
the,O
population,O
is,O
infected,O
and,O
that,O
the,O
time,O
from,O
exceeding,O
32.5,PERCENT
%,PERCENT
of,O
the,O
population,O
being,O
infected,O
to,O
exceeding,O
65,PERCENT
%,PERCENT
of,O
the,O
population,O
being,O
infected,O
is,O
equal,O
to,O
the,O
amount,O
of,O
time,O
from,O
March,DATE
1st,DATE
to,O
exceeding,O
32.5,PERCENT
%,PERCENT
infected,O
.,O
The,O
projection,O
as,O
‐,O
sumes,O
an,O
infection,CAUSE_OF_DEATH
fatality,O
rate,O
of,O
0.8,PERCENT
%,PERCENT
in,O
order,O
to,O
determine,O
the,O
total,O
number,O
of,O
cases,O
.,O
[,O
13,NUMBER
],O
Based,O
on,O
2019,DATE
GDP,O
.,O
[,O
14,NUMBER
],O
Sourced,O
from,O
the,O
2010,DATE
Census,O
.,O
Since,O
the,O
CDC,ORGANIZATION
data,O
provides,O
the,O
share,O
of,O
deaths,O
by,O
age,O
and,O
sex,O
in,O
age,O
bins,O
(,O
i.e.,O
males,O
age,O
15,NUMBER
‐,O
24,NUMBER
),O
.,O
we,O
have,O
to,O
calculate,O
the,O
average,O
QALY,O
lost,O
within,O
the,O
bin,O
.,O
These,O
values,O
allow,O
us,O
to,O
estimate,O
QALY,ORGANIZATION
lost,O
within,O
a,O
bin,O
(,O
rather,O
than,O
just,O
at,O
a,O
single,O
age,O
),O
.,O
[,O
15,NUMBER
],O
Based,O
on,O
probability,O
of,O
death,O
estimates,O
from,O
the,O
Social,ORGANIZATION
Security,ORGANIZATION
Administration,ORGANIZATION
.,O
These,O
values,O
are,O
used,O
.,O
in,O
conjunction,O
with,O
the,O
quality,O
of,O
life,O
adjustments,O
and,O
share,O
of,O
population,O
in,O
each,O
age,O
‐,O
sex,O
category,O
.,O
to,O
calculate,O
the,O
weighted,O
average,O
present,DATE
value,O
quality,O
‐,O
adjusted,O
life,O
expectancy,O
for,O
each,O
age,O
bracket,O
.,O
Due,O
to,O
the,O
large,O
number,O
of,O
age,O
‐,O
sex,O
combinations,O
.,O
we,O
do,O
not,O
present,DATE
the,O
values,O
here,O
.,O
(,O
2015,DATE
),O
.,O
Due,O
to,O
the,O
large,O
number,O
of,O
estimates,O
.,O
we,O
do,O
not,O
present,DATE
the,O
values,O
here,O
.,O
For,O
males,O
.,O
the,O
values,O
range,O
from,O
0.94,NUMBER
at,O
age,O
20,NUMBER
and,O
younger,O
to,O
0.60,NUMBER
at,O
age,O
90,NUMBER
and,O
older,O
.,O
For,O
females,O
.,O
the,O
values,O
range,O
from,O
0.95,NUMBER
at,O
age,O
20,NUMBER
and,O
younger,O
to,O
0.64,NUMBER
at,O
age,O
90,NUMBER
and,O
older,O
.,O
Model,TITLE
Results,O
Between,O
Full,O
Reopening,O
and,O
Limited,O
Reopening,O
Scenarios,O
Estimate,O
of,O
COVID,O
‐,O
19,NUMBER
Deaths,O
if,O
Vaccine,O
Widely,O
Available,O
in,O
12,DURATION
Months,DURATION
Estimate,O
of,O
COVID,O
‐,O
19,NUMBER
Deaths,O
if,O
Vaccine,O
Widely,O
Available,O
in,O
36,DURATION
Months,DURATION
Total,O
Additional,O
Non,O
‐,O
COVID,O
‐,O
19,NUMBER
Deaths,O
Due,O
to,O
Avoiding,O
Hospital,O
or,O
System,O
Overload,O
Total,O
expected,O
lost,O
QALY,O
if,O
vaccine,O
widely,O
available,O
in,O
12,DURATION
months,DURATION
(,O
present,DATE
value,O
),O
Total,O
expected,O
lost,O
QALY,O
if,O
vaccine,O
widely,O
available,O
in,O
36,DURATION
months,DURATION
(,O
present,DATE
value,O
),O
QALY,O
savings,O
over,O
unmitigated,O
if,O
vaccine,O
widely,O
available,O
in,O
12,DURATION
months,DURATION
(,O
present,DATE
value,O
),O
QALY,O
savings,O
over,O
unmitigated,O
if,O
vaccine,O
widely,O
available,O
in,O
36,DURATION
months,DURATION
(,O
present,DATE
value,O
),O
Monetary,O
value,O
of,O
QALY,O
gains,O
versus,O
unmitigated,O
if,O
vaccine,O
widely,O
available,O
in,O
12,DURATION
months,DURATION
(,O
present,DATE
value,O
.,O
billions,O
.,O
USD,O
),O
Monetary,O
value,O
of,O
QALY,O
gains,O
versus,O
unmiti,O
‐,O
gated,O
if,O
vaccine,O
widely,O
available,O
in,O
36,DURATION
months,DURATION
(,O
present,DATE
value,O
.,O
billions,O
.,O
USD,O
),O
QALY,O
gained,O
versus,O
unmitigated,O
per,O
capita,O
if,O
vac,O
‐,O
cine,O
widely,O
available,O
in,O
12,DURATION
months,DURATION
(,O
days,DURATION
of,O
life,O
),O
QALY,O
Gained,O
versus,O
unmitigated,O
per,O
capita,O
if,O
vaccine,O
widely,O
available,O
in,O
36,NUMBER
months,DURATION
(,O
days,DURATION
of,O
life,O
),O
Monetary,O
value,O
of,O
QALY,ORGANIZATION
gained,O
versus,O
unmit,O
‐,O
igated,O
per,O
capita,O
if,O
vaccine,O
widely,O
available,O
in,O
12,DURATION
months,DURATION
(,O
USD,O
),O
Monetary,O
value,O
of,O
QALY,ORGANIZATION
gained,O
versus,O
unmitigated,O
per,O
capita,O
if,O
vaccine,O
widely,O
available,O
in,O
36,DURATION
months,DURATION
(,O
USD,O
),O
Months,DURATION
of,O
current,DATE
policy,O
before,O
policy,O
fails,O
cost,O
‐,O
benefit,O
analysis,O
Full,O
Reopening,O
&,O
Reduced,O
Social,O
Limited,O
Reopening,O
